Monoclonal antibody (MoAb) M27 was generated after immunization of mice with the human B-lineage acute lymphoblastic leukemia cell line Pre-ALP. Under reducing conditions, MoAb M27 precipitated a 60-kD surface-membrane molecule from Pre-ALP cells. Expression cloning of Pre-ALP cDNA showed that M27 recognizes carboxypeptidase M (CPM), a cell-surface, zinc-dependent protease known to cleave off basic C-terminal amino acids from peptide hormones. Using M27 antibody, CPM was detected only at discrete B lymphocyte developmental stages, namely on committed precursors and on germinal center cells. CPM was also expressed on mature T cells, mainly after activation. These results provide the first description of a carboxy-P EPTIDE HORMONES, produced by multiple tissues, play an important role in the regulation of immune response^."^ The activity of most peptide hormones is locally controlled by peptidases, some of which work in concert to digest common substrates." Many peptidases have been identified and characterized in kidney, lung, and pla~enta.~ In addition to their presence in these tissues, several peptidases are expressed in different hematopoietic cell types at specific stages of lymphoid or myeloid differentiation. Such peptidases include CDlO/neutral endopeptidase 24.1 l (CDlONEP), CD13/aminopeptidase N (CD13/APN), BP-l/ 6C3/aminopeptidase A (E-AP), and CD26/dipeptidylpeptidase The latter enzymes belong to the type I1 integral membrane glycoprotein family. Three of them (CD10, CD13, and BP-l) contain a pentapeptide signature sequence, characteristic of members of the zinc-binding metalloprotease family. CDlO and CD13 can hydrolyze a variety of substrates, including opioid peptides and enkephalin. Of particular interest, CDlO and CD13 are known to act in concert, as exemplified by degradation of the chemotactic peptide (Met-Leu-Phe), resulting in limitation of neutrophil inflammation response^.*^^ Carboxypeptidase M (CPM) is another cell-surface, zincdependent protease found in many tissues and cultured cells. CPM cleaves COOH-terminal arginine or lysine from several peptide hormones (bradykinin, enkephalin, dynorphine-A). In the present study, we have generated a monoclonal anti- body (MoAb) directed against CPM and report that this protease is also broadly expressed on human leukocytes. Of interest, CPM was observed only on CD38+ leukocytes. Finally, the pattern of CPM distribution was strongly reminiscent of CDlO on lymphoid cells and CD13 on myeloid cells, suggesting cooperation for the cleavage of common substrates.
peptidase on lymphoid cells. In addition, CPM was found on granulocytes and monocytes, but not on their progenitors. Strikingly, CPM was present only on CD38' cells, irrespective of lineage affiliation. Of interest, CPM displayed a largely overlapping distribution with the CDlO and CD13 peptidases, with which it shares common substrates (enkephalins, bradykinin). Collectively, the present data show a previously unrecognized distribution pattern of CPM on lymphoid and myeloid cells and suggest that CPM may cooperate with CD10 and CD13 to regulate biologic activity of peptide hormones on leukocytes.
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body (MoAb) directed against CPM and report that this protease is also broadly expressed on human leukocytes. Of interest, CPM was observed only on CD38+ leukocytes. Finally, the pattern of CPM distribution was strongly reminiscent of CDlO on lymphoid cells and CD13 on myeloid cells, suggesting cooperation for the cleavage of common substrates.
MATERIALS AND METHODS

Human Cells
Pre-ALP, a t(1;19) pre-B leukemic cell line, was raised in our laboratory (Schering-Plough, Dardilly, France).'" The Jurkat (T cell), HL60 (myeloid), and K562 (myeloid) cell lines were obtained from American Type Culture Collection (ATCC; Rockville, MD). All cell lines were cultured in RPM1 1640 medium (GIBCO, Grand Island, NY) supplemented with 10% (voVvol) heat-inactivated fetal calf serum (FCS; GIBCO), 2 mmol/L L-glutamine, 100 U/mL penicillin, and 100 pg/mL streptomycin (hereafter referred to as complete medium). Cells were used for experiments during log phase of growth.
Peripheral blood mononuclear cells (PBMC) were isolated from healthy donors by Ficoll-Hypaque density gradient (Eurobio, Paris, France).
Mature B cells were purified from tonsils obtained from children undergoing tonsillectomy by sheep red blood cell rosetting and immunomagnetic bead depletion of residual non-B cells."
Normal CDlO+slg-B-cell precursors and CD34' progenitors were isolated, respectively, from mid-term fetal bone marrow (FBM) and adult bone marrow, as previously described.","
All human biologic material was obtained according to institutional guidelines.
Immunoprecipitation Analysis
Round-bottomed 96-well polyvinylchloride plates (Dynatech Laboratories, Chantilly, VA) were coated overnight at 4°C with I O 0 p&/ mL antimouse IgG (Sigma). Five micrograms of purified MoAb were subsequently incubated at 4°C for 4 hours. Alb-l (anti-CD10) (Immunotech, Marseille, France) was used as positive and Immu 133.3 (anti-CD34) (Immunotech) as negative control murine MoAbs. Saturation was performed for 2 hours with 1 % vollvol normal mouse serum in phosphate-buffered saline (PBS) containing I mmol/L NaN3. Pre-ALP cells, previously surface-labeled with 2 mCi IzINa (Amersham. Les Ulis, France) in the presence of 2 U/mL lactoperoxidase (Sigma) and H202 (Sigma), were lysed (4OC) with a lysis buffer (l50 mmol/L NaCI: 50 mmol/L Tris, pH 7.6: I % Nonidet P-40) containing I mmol/L phenylmethylsulfonyl fluoride (PMSF), 0.5 mmol/L EDTA, 1 pmol/L leupeptine. and I pmol/L pepstatine A. The nuclei were pelleted, and supernatant was incubated in the antibody-coated 96-well plates ( 1 0 0 p L per well, overnight at 4°C). Immune complexes were harvested in glycine 0.1 mol/L at room temperature and analyzed under reducing conditions by sodium dodecyl sulfate-polyacrylamide ( l 2.5% wt/vol) gel electrophoresis (SDS-PAGE) and autoradiography.
cDNA Library Construction and Expression Cloning System
Poly (A)' RNA from Pre-ALP cells was converted into doublestranded cDNA using Not I oligo(dT) primers and a cDNA synthesis kit (BRL, Gaithersburg, MD). The double strand was ligated with Bstxl linkers and size-fractionated by spin column (Spin 400; Clontech, Palo Alto. CA). The cDNAs longer than 400 bp were cloned into the Bsrx-Not I site of pME18s. an SV40-based mammalian expression vector,I4 and plasmids were subsequently transfected into COS7 cells. Clones encoding M27 antigen were isolated from the cDNA library by selection of transfected COS7 cells reactive with M27 MoAb though cell-sorting on a flow cytometer (FACStar+; Becton Dickinson, Sunnyvale, CA), according to a previously described strategy.Is The cDNA was isolated from the M27' COS7 cells. and sequencing was performed on both strands by the dideoxynucleotide method using a Taq Dye Deoxy Terminator Cycle Sequencing kit (Applied Biosystems, Foster City, CA). Sequencing products were analyzed by an automated sequencer (Applied Biosysterns).
Phenotype Analysis
Cell suspensions. Single-color surface immunofluorescence was performed according to standard techniques using IO pg/mL MoAbs analyzed with a FACScan flow cytometer (Becton Dickinson). Positive cells were determined by reference to nonspecific staining by control MoAbs of the same isotype but unrelated specificity.
Immunohistology. Cryostat sections, 5 to IO pm thick, were performed on human tonsils obtained as described above. After fixation (20 minutes in acetone at 4°C). sections were incubated sequentially with MoAb M27 (IO pLg/mL), biotinylated sheep antimouse Ig (Binding Site, Birmingham, UK), and peroxidase-conjugated streptavidin (Sigma). Staining was developed using DAB chromogen (Dako), yielding a brown color.
RESULTS
Generation of M27 Antibody
As a strategy to identify potentially novel surface-membrane molecules on human B-lineage precursors, mice were immunized with the pre-B acute lymphoblastic leukemia (ALL) cell line Pre-ALP, and hybridomas were generated as described above. MoAb M27, of IgG, isotype, was found to react strongly with all Pre-ALP cells by surface immunofluorescence, but stained neither the T-cell line Jurkat nor the myeloid HL60 and K562 cells (data not shown). The M27 antibody precipitated a 60-kD molecule from '*'I surface-labeled Pre-ALP cells, as determined by SDS-PAGE under reducing conditions (Fig l) . An extensive phenotypic analysis was subsequently performed on Pre-ALP cells using a broad panel of antileukocyte MoAbs, but none of the antiFor personal use only. on November 11, 2017 . by guest www.bloodjournal.org From gens thus detected on Pre-ALP had a known molecular mass in the 60-kD range. These data raised the possibility that MoAb M27 recognizes a molecule not previously identified on B-cell precursors, and the antibody was consequently selected for further study.
Antibody M27 Recognizes CPM
To identify the molecule recognized by MoAb M27, a cDNA library was established from Pre-ALP polyA mRNA. After four cycles of selection of COS7 transfectants as described in Materials and Methods, a cDNA clone was found to encode a protein reactive with M27 MoAb by immunofluorescence (data not shown). Nucleotide sequencing of the M27-reactive clone showed a 2-kb cDNA insert (clone 17) of 2,020 bp that included a 1,329-bp open reading frame. A computer search showed that the coding region of clone 17 displays 99.9% homology with CPM.16 When compared with the CPM sequence previously described, clone 17 cDNA contains the ATG initiation codon and four additional downstream codons (GAC, TTC, CCG, and TGC). As a consequence, the nucleotide sequence of clone 17 predicts a cysteine residue at position 5 instead of a glycine, as previously reported. Clone 17 thus encodes a full-length CPM sequence of 443 amino acids. These data are consistent with the 60-kD band precipitated by MoAb M27 (Fig l) , as CPM has been reported to have a 62-kD molecular weight. 16 As CPM is attached to plasma membranes via a phosphatidylinositolglycan (PI-G) anchor on several other cell types,I6-l9 we investigated the anchoring of CPM on Pre-ALP B-lineage cells. Thus, membrane-bound CPM on Pre-ALP was found to be released by phosphatidylinositol-specific phospholipase C (PI-PLC), indicating that it is anchored to the membrane via PI-G (data not shown).
The present findings show that MoAb M27 is directed against CPM and represent the first description of a carboxypeptidase on lymphoid cells.
CPM Is Expressed at Discrete Stages of B Lymphoid Development
As CPM was detected on the pre-B leukemia cell line Pre-ALP (Fig 2A) , we investigated whether this expression is shared by normal B-lineage precursors. Indeed, as shown in Fig 2B, virtually all B lymphoid precursors (CD10+, CD19+, slg-cells) isolated from bone marrow reacted with M27 antibody. In contrast, only a small proportion of peripheral blood B cells (CD19+) expressed CPM (Fig 3A) , and the majority of the M27' cells observed in the periphery were not of B-lineage affiliation (CD19-).
To further characterize the M27+ mature B lymphocytes, tonsil sections were examined for expression of CPM. Strikingly, M27 reactivity was found to be associated only with germinal centers and epithelial cells, whereas follicular mantle areas did not stain with the antibody (Fig 3B) . Finally, purified tonsillar plasma cells did not stain with M27 antibody (data not shown).
As the observed pattern of CPM distribution is strongly reminiscent of CD10 in normal B-cell development, expression of these two metallopeptidases was analyzed on a panel of B-lineage malignancies. The large majority of the CPM+ samples were found to express CD10, but a dichotomy was observed in some of the cases (Reh, Daudi, Raji, and Bae; Table l (BL) and one of four of the chronic lymphocytic leukemia (CLL) samples examined]. Finally, all CPM' B-lineage malignancies expressed CD38 (Table l) . Collectively, these data indicate that CPM is present on B lymphoid progenitor/ precursor stages, downregulated on circulating B cells, and reexpressed during the germinal center reaction.
Mature T Lymphoc?ltes Express CPM Preferentidy After Activation
We next addressed whether CPM expression is restricted to B-lineage lymphoid cells. Thymocytes were not stained by M27 antibody, which reacted exclusively with the epithelial Hassall's corpuscles in thymus sections (data not shown). However. in contrast with T-lineage precursors, a minor subset of peripheral blood T lymphocytes was found to be M27' (Fig 4A) . The CPM' T cells were contained within the CD4' subset (13% of CD4' cells). Notably, the proportion of T cells reactive with MoAb M27 was increased after activation by phytohemagglutinin (PHA) (Fig 4B) . This effect was most striking on the CD4' population (38% M27' cells) and included a marked upregulation of CPM expression levels. In addition, a minor subset of CD8' cells (3% of CD8' cells) was also found to express CPM after activation ( Fig  4B) . In line with above observations, two of three CD4' Tcell clones tested were found to markedly upregulate CPM expression after anti-CD3 activation (data not shown).
Collectively, these data indicate that CPM expression is not restricted to B-lineage cells during lymphoid development and that mature T lymphocytes upregulate expression of this protease after activation.
CPM I s Present on Myeloid Cells, Rut Not on Their Progenitors
We next investigated whether CPM expression is also a feature of myeloid cells. Indeed, most cells of monocytic affiliation (CD14'). either from peripheral blood (Fig 5A) or bone marrow (Fig SB) , stained with M27 antibody. A similar M27 reactivity was observed among CD14' tonsil cells (data not shown). In addition, cells of the granulocytic series (CD15') also expressed CPM. However, whereas all CD15' peripheral blood cells were M27' (Fig SA) , only a proportion of bone marrow granulocytic cells stained with M27 antibody (Fig 5B) .
In contrast with mature myeloid cells, CD34' hematopoietic progenitors lacking CD19' early B-lineage cells did not stain with M27 antibody (data not shown). Also, CD34' progenitors cultured under conditions resulting in the emergence of immature myeloid cells"' did not gain M27 reactivity. Consistent with the observations that myeloid progenitors/precursors do not express CPM, M27 antibody reacted only with cells from a single case of acute myeloid leukemia (AML) among eight patients tested (data not shown).
Finally, we investigated whether the distribution of CPM parallels that of the CD13 zinc-dependent aminopeptidase on myeloid cells. Virtually all CD 13' peripheral blood cells were M27', either in peripheral blood (Fig SA) or bone CD8-FITC marrow (Fig 5B) . However, in analogy with CDlO' B lymphoid malignancies, several CD13' AML cases did not react with M27 antibody (data not shown).
Collectively, these data indicate that CPM is present on CD13' myeloid lineage cells, although not in strict association, and that CPM acquisition is a relatively late event in myelopoiesis.
CPM Expression Is a Feature of CD38' L.eukocytes
As demonstrated above, CPM was present on B-cell precursors and germinal center cells, which are known to express 
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the membrane glycoprotein CD38. These findings evoked the possibility that expression of the two molecules might be more broadly associated on different leukocyte lineages. Indeed, as shown in Fig 6, M27 reactivity was restricted to cells expressing CD38, and a very similar staining pattern was observed in peripheral blood (Fig 6A) , tonsil (Fig 6B) , and bone marrow ( Fig 6C) . As M27' cells from these tissues were shown above to include B lymphoid, T lymphoid, and myeloid cells, these data imply that CPM restriction to CD38' cells is a feature of different leukocyte lineages.
Of interest. this restriction of M27 reactivity was also found on leukemic cells, as all M27' malignant cells tested were CD38' ( Table l) . In this context, the only CLL case observed to be M27' (patient Bae, Table I ) was unique among the four CLL cases analyzed in that it expressed CD38. However, whereas all CPM' leukocytes expressed CD38, the converse was not found to be the case (Fig 6) .
indicating that the two molecules are not strictly associated.
Collectively, these data indicate that the presence of CPM is a feature of CD38' leukocytes irrespective of lineage affiliation.
DISCUSSION
This report describes the generation of a murine MoAb, M27, directed against the cell-surface membrane enzyme CPM. The specificity of the antibody was deduced from its reactivity with a protein encoded by a cDNA clone which was isolated from the human B-lineage ALL cell line Pre-ALP"' and which presented 99.9% homology with the previously described nucleotide sequence of placental CPM.'" CPM has been described in several different tissues, including placental microvilli? brain and peripheral n e r v e~, '~ and alveolar type I pneumocytes." Although alveolar macrophages have been shown to react with polyclonal anti-CPM antibody in human lung sections" and CPM-like activity described in purified rat lung macrophages:' the distribution of the enzyme on lymphohematopoietic cells has not previously been explored.
Here we have shown that MoAb M27 reacts with a variety of cell types of hematopoietic origin, hence implying that CPM displays a considerably wider distribution on leukocytes than previously suspected. Notably, the present description of CPM expression on lymphoid cells represents the first report of a carboxypeptidase on lymphocytes. CPM is another striking example of a zinc-dependent, surfacemembrane peptidase expressed during human lymphohematopoietic development, in addition to the well-described CD 1 O/NEP, CD 13/APN, and the more recently characterized Among the considerable number of known zinc-dependent enzymes, CPM and the above leukocyte peptidases all belong to the hydrolase (class Ill) group and, in addition, share a tridentate active zinc site of three amino acid residues, in contrast with enzymes in which zinc is coordinated to four cysteine residues. However, CPM differs from CDIO, CD13, and E-AP in that the first two zinc-binding residues of CPM are separated by a two-amino acid spacer, instead of three in the other pro tease^.'.'^ Furthermore, CDIO, CD13, and E-AP are type ll integral membrane proteins, whereas CPM is bound to the cell membrane via a PI-G anchor, analogous to the CD73 ecto 5'-nucleotidase also found on lymphoid cells. These considerations suggest a closer evolutionary relationship between CDIO, CD13, and E-AP than between these three enzymes and CPM.
Of interest, CPM was found to be largely coexpressed with CD10 and CD13, respectively, on B lymphoid and myeloid cells. Indeed, our findings indicate that the large majority of cells that express CD10 or CD13 are CPM', suggesting that CPM may act in concert with these proteases. In this context, it is noteworthy that the three peptidases cleave off amino acids at different locations, and that CPM, CDIO, and CD13 share common substrates, which include opioid peptides (enkephalins) and bradykinin. As these peptides have multiple physiologic effects on hematopoietic cells," it can be speculated that CPM contributes to local regulation of such biologic activities through modification of binding to their receptors. In this context, CPM-mediated cleavage of C-terminal Arg from bradykinin is known to result in alteration of receptor specificity.'" CPM was observed to display a distinctive expression pattern on hematopoietic cells. The enzyme was found to be acquired early in B lymphoid ontogeny, whereas expression was absent from thymocytes and myeloid progenitors. These results strongly suggest that CPM plays a particular role in B lymphopoiesis. In this context, CD10 has recently been shown to negatively regulate murine B cell ~n t o g e n y . *~.~~ Our data further indicate that CPM expression is downregulated on circulating B cells and reexpressed (as is CDIO) on germinal center B cells. Thus, peptidases are likely to be E-AP.6.23
For personal use only. on November 11, 2017 . by guest www.bloodjournal.org From important in the germinal center reaction of B cells after activation by antigen, although their role is presently not understood. Within the T lymphoid lineage, CPM was found to be strongly upregulated after activation of mature cells, most strikingly within the CD4+ subset. Of interest, CD13 has also been shown to be upregulated after activation of T lymphocyte^.^^ Activated T cells are known to synthesize precursor forms of opioid pep tide^,^' raising the possibility that CPM could play a function in the transformation of such propeptides. Finally, CPM was found to be expressed on myeloid cells of the granulocytic (CD1.5') and monocytic (CD14+) lineages, although acquisition of the enzyme appears to be a relatively late event in myelopoiesis. Neutrophil-mediated inflammatory responses are known to be limited by CD13 and CD10, which are both present on these cell^.^^" In addition, CD13 has been reported to enhance antigen processing by monocytes?' It will be of interest to investigate whether similar activities are borne by CPM on myeloid cells.
Strikingly, we observed that, irrespective of their lineage, all leukocytes expressing CPM expressed CD38, a type I1 membrane gly~oprotein~~ whose extracellular domain catalyzes the synthesis of cyclic adenosine diphosphate-rib0se.3~ It is of interest that CD38 and CPM are expressed in bone marrow and in germinal centers of secondary lymphoid organs, which both represent sites of highly proliferative cells. Collectively, the present data demonstrate that CPM is another major, and previously unrecognized, leukocyte surface-membrane, zinc-dependent metallopeptidase. As it appears likely that CPM contributes to a number of regulatory processes within the immune system, it will be important to dissect its role in cellular interactions involving leukocytes expressing this protease.
